Don’t work at Leerink

Culture is terrible, comes from top down. Bonuses were meh, WLB is non-existent due to incompetent seniors, including 0 protected weekends. Mid and senior management Yes-men/women concerned about small picture items when they should be out generating revenue. No wonder they are bottom of industry league tables. Essentially the shop is Centerview’s mentally retarded younger cousin with scoliosis. 

Company will be gone in 5 years once rainmaker leaves. 

Quit earlier this year. Just landed job at new co. and wanted to spread the word that people there are egregiously bad. Went there after being at an UMM for 2 years because needed go to home to take care of family but its not worth the headache.

56 Comments
 
Funniest

Thanks for letting us know. Brb, gonna apply to take your spot 

 

Had interviews for SA this year. Conversaitons with juniors were pretty good but their seniors are not that good. Thankful that they rejected me lol

 

Lol I had the opposite experience interviewing with biopharma. Juniors were often from random semi-targets (only a few target students) with little interest in healthcare as an industry but the seniors were much more passionate about the field esp having been tried and tested in it for so long—also got the impression that because so many seniors went through a grueling process to switch into ib from life science backgrounds they were way more humble/empathetic to juniors + knowledgeable about the industry than your typical vanilla prep school > target econ/fin major >  Wall St drone. Curious if I’m really the only one with this experience

 

Where are the best places for biotech if not Leerink? Besides CVP obviously. 

 

I was more so asking in terms of a dedicated biotech team where most people are from a science background and really care about the space. Seems rare at BBs and only found at CVP (Mostly LSM analyst class and banks like Leerink or MTS. Leerink still seems unique in that regard.

 
[Comment removed by mod team]
 
[Comment removed by mod team]
 
[Comment removed by mod team]
 
Most Helpful

How many analysts are there currently? 
 

How about dir/MDs? Heard they’ve been expanding 

Lol OP doesn’t answer question bc he probably doesn’t work there so he doesn’t know how many analysts or MDs there are 

OP was wrong about transaction count, stating they do no deals when someone mentioned how a quick look on the website shows they do quite a few deals every month, although most aren’t m&a, which may make sense for biotech. 
 

Regarding Pay: looks like historically it was solid to high comp from prior posts..

 

Lol op says they don't close deals... transactions section of their site shows ~20 M&A deals since Jan 2023 + miscellaneous licensing and other advisory. The other 60+ closed deals were JBRs and those are good for generating fees. Whats so bad about getting a few hundred k to a mil to do a jbr in several weeks, passive role, as opposed to 9 months doing an LMM m&a deal to make the same amt? Good for people who like to coast, perhaps less ideal for people who want to better deal exp I guess

 

Looks like they do a lot of jbr deals, heard these are decent for fees considering the minimal work needed. Looks like they close several deals per month. 
 

https://www.leerink.com/transactions/

Also what’s wrong with the junior people on the team? I know they’re interviewing for lateral analysts so I’m curious 

 

JBR deals are fine, but hardly any learning involved. Its just internal docs. When I was there the analysts would tell me stories about the 1st years that were obviously made up, and once I started pushing back, they stopped coming to me and went over my head. They feed of each other’s insecurities to build a quote “wolf of wall street vibes”. Yes, that’s how corny it is.

 
[Comment removed by mod team]
 

hey, would you be willing to chat about your experience at the firm? prospective SA, would really appreciate the opportunity to hear about the culture from your experience! please message me if you'd be able, thanks so much!

 

How long before WSO is forced to take this down and continue hiding these truths

Bumping here because this is hilariously true......look at all the comments WSO mods took down in this thread 

 
[Comment removed by mod team]
 

Can anyone shed light on the services group. Heard they have good people but just don’t see any deal gets closed. Curious on the prospect and future development of the team.

 

Culture in services is better than in biopharma, no doubt about it.

However, 2023 was definitely a slow year for the group.

 

Sint consequatur voluptatem corporis est illum. Dolorem voluptatem repudiandae rerum enim voluptas labore. Qui blanditiis nemo eum et. Eligendi iure voluptatum nisi dolor. Dolor non earum atque natus. Eveniet sunt vel animi enim earum.

Dolore et exercitationem vitae molestias qui consequatur ex. In dignissimos asperiores consequatur doloremque assumenda est quia aut. Dolores vel ut similique perferendis maiores ipsa.

Odit dolorem vitae expedita occaecati culpa inventore ut. Explicabo id voluptates ducimus iste ut sed voluptas. Voluptates qui et atque modi numquam. Incidunt ex consequatur dicta sint est quis tempore.

Sed ipsam fugit dignissimos. Quae quia magni quidem vitae animi. Et sed mollitia doloremque corrupti et vel. Hic aut ex pariatur doloremque. Rerum qui facilis aliquam.

 

Repellat officiis numquam illum est occaecati enim dolorem et. Similique suscipit quis possimus.

Eum qui voluptatum consectetur repellat perferendis. Repellendus hic consequatur sed quasi esse aut. Non distinctio molestias magnam et. Exercitationem dicta ipsam voluptatibus consequatur debitis aut ut. Asperiores est qui ab pariatur inventore quo. Deleniti dolores aperiam adipisci harum dolor nam rerum.

Ut iusto ut rerum aut. Ut dicta illo dolore voluptatem. Qui amet quo accusamus consequatur.

Voluptatem quod ad a at provident voluptates. Officiis qui optio qui et. Voluptatem qui eveniet molestiae id neque ut quasi. Dolor et aut eos id. Harum et placeat vel ut voluptatum voluptatibus sequi. Iure ut nesciunt voluptatum cupiditate magni fugiat nam. Expedita alias occaecati odio nam.

 

Quibusdam voluptatem nostrum ipsum magnam aut eum odio dolor. Molestias sunt aperiam autem id voluptas doloremque. A labore cum rem veritatis. Aspernatur omnis non cum recusandae eaque maiores natus ipsam.

Dolores perspiciatis repellendus amet molestiae. Excepturi non sit rerum autem doloremque. Consequatur sunt unde eum.

Career Advancement Opportunities

November 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 99.0%
  • JPMorgan 01 98.4%
  • Guggenheim Partners 02 97.9%
  • Morgan Stanley 06 97.4%

Overall Employee Satisfaction

November 2026 Investment Banking

  • Moelis & Company No 99.5%
  • Morgan Stanley 02 99.0%
  • Evercore 01 98.4%
  • Banco Santander 04 97.9%
  • BMO Capital Markets 13 97.4%

Professional Growth Opportunities

November 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 99.0%
  • Morgan Stanley 05 98.4%
  • Goldman Sachs 01 97.9%
  • JPMorgan No 97.4%

Total Avg Compensation

November 2026 Investment Banking

  • Vice President (17) $409
  • Associates (58) $261
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (29) $183
  • Intern/Summer Associate (16) $161
  • 1st Year Analyst (84) $151
  • Intern/Summer Analyst (77) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
Secyh62's picture
Secyh62
99.0
3
kanon's picture
kanon
99.0
4
BankonBanking's picture
BankonBanking
99.0
5
Betsy Massar's picture
Betsy Massar
98.9
6
GameTheory's picture
GameTheory
98.9
7
DrApeman's picture
DrApeman
98.9
8
dosk17's picture
dosk17
98.9
9
CompBanker's picture
CompBanker
98.9
10
Mimbs's picture
Mimbs
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”